180 Life Sciences announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company’s common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ATNF:
- 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
- 180 Life announces publication of review on biological basis of Dupuytren
- 180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
- 180 Life Sciences CEO says priorities continue to be clinical programs
- 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
